The antidepressant venlafaxine is known to increase the turnover of cerebral monoamines, which are catabolized by the catechol-O-methyltransferase (COMT). The COMT (Val(108/158)Met, rs4680) genetic polymorphism affects the cerebral COMT activity. But whether this genetic polymorphism is associated with response to venlafaxine remains unclear. We assessed the impact of the COMT Val(108/158)Met, rs4680 genetic polymorphism on the efficacy of venlafaxine in depressed patients. This study was nested in the METADAP cohort, a real-world naturalistic treatment study in psychiatric settings. A total of 206 Caucasian patients with a unipolar major depressive episode (DSM-IVTR) treated with venlafaxine and evaluated with the Hamilton Depression Rating Scale (HDRS) were studied. One hundred and eighty patients were genotyped for the COMT Val (108/158)Met, rs4680 genetic polymorphism and classified into three genotype subgroups: Val/Val, Val/Met and Met/Met. The COMT genotype was the explanatory variable, and the variables to be explained were HDRS score, HDRS score improvement over time, response rate and remission rate. Venlafaxine had a trend to higher efficacy in the Val/Val patients as compared to Met/Met carriers, as shown by the HDRS score improvement after 3 months of treatment, but this result was not significant in mixed models [Val/Val: 59.78% (AE22.4); Val/Met: 51.64% (AE26.3); Met/Met: 39.52% (AE27.6)]. The percentage of responders and remitters after 3 months of treatment was not significantly different in the three genotype groups, although coherent trends were shown. The COMT Val(108/158)Met, rs4680 genetic polymorphism cannot be recommended as a biomarker for the prediction of venlafaxine efficacy in patients treated in psychiatric settings.
Major depressive disorder (MDD) is the most common psychiatric disorder with a life-time prevalence of around 16% [1] . This disorder has a heavy impact on the individual wellbeing and has been predicted to become the second leading cause of the global burden of disease by the year 2020 [2] . MDD is a multi-factorial disease influenced by genetic, environmental and physiological factors [3, 4] .
Unfortunately, response to antidepressant drugs (ADD) in patients suffering from MDD remains insufficient as up to one-third of patients adequately treated for major depressive disorder (MDD) do not respond to multiple interventions [5] . This variability of ADD response partly relies on specific socio-demographic and clinical factors [5] but also on genetic factors [6, 7] .
Many pharmacogenetic studies have examined the association between antidepressant response and candidate genes involved in the serotoninergic system, but only few studies have focused on dopaminergic or noradrenergic systems [3, 8] . The catechol-O-methyltransferase (COMT) inactivates norepinephrine and dopamine via methyl conjugation and therefore is a promising candidate for pharmacogenetic studies [9, 10] .
A single functional genetic polymorphism, rs4680 (427G>A) causes an aminoacid change from valine to methionine in codon 158 (Val158Met) for the membranebound isoform (MB-COMT) and in codon 108 (Val108Met), corresponding to codon 158 of MB-COMT, for the soluble isoform (S-COMT). It was shown in vitro that the COMT Val (108/158)Met genetic polymorphism influences the enzyme activity: high activity for the Val/Val carriers, intermediate activity for the Val/Met carriers and low activity for the Met/ Met carriers. Carriers of Met allele have three to four times lower enzymatic activity than those of Val allele [6] .
Clinical studies testing an association of COMT Val(108/ 158)Met, rs4680 genetic polymorphism with antidepressant response also showed contrasting results in MDD patients. One possible explanation for the contradictory results could be the rather broad definition of MDD and in the complex way of defining a MDD [7] .
Eight studies showed a positive association between COMT Val(108/158)Met, rs4680 and antidepressant response evaluated on HDRS score [11] [12] [13] [14] [15] [16] [17] [18] . Three studies reported a better response in Val carriers in depressed patients [15] [16] [17] . One study reported that Val/Val genotypes had a better improvement on HDRS score than Met/Met genotypes with venlafaxine (n = 126 patients, n = 128 placebo [17] ), another one showed a better response to mirtazapine in Val carriers (n = 53 [15] ), and one metabolomic study evaluating duloxetine HDRS response and plasma metabolites showed that Val/Val Japanese patients have increased plasma concentration of a catecholamine metabolite 3-methoxy-4-hydroxyphenylglycol (n = 64 patients and n = 30 controls), showing that the Val/Val genotype is more sensitive to the influence to duloxetine treatment on noradrenergic neurons but not the HDRS response [16] .
In another way, five studies reported a better response in Met/Met carriers for Caucasian patients treated with milnacipran for 6 weeks (n = 81 [11] ), the SSRI paroxetine for 1 month (n = 55 [13] ), the SSRI fluvoxamine for 6 weeks (n = 55 [14] ) and an inhibitor not specified for 8 weeks (n = 25 [18] ) and Chinese patients treated with fluoxetine after 8 weeks of treatment but not after 4 weeks (n = 334 [12] ).
On the other hand, ten studies showed no association between COMT Val(108/158)Met, rs4680 genetic polymorphism and antidepressant response evaluated on the HDRS score on depressed patients [15, [19] [20] [21] [22] [23] [24] [25] , with different treatments on the MADRS (Montgomery-Asberg Depression Rating Scale) that evaluates the severity of depressive episodes [26] and on the HAM-A (Hamilton Anxiety Rating Scale) [27] that evaluates the severity of a patient's anxiety. No effects were reported on response to venlafaxine and paroxetine on Korean patients (n = 184 patients and n = 200 healthy controls [19] ); to venlafaxine and other antidepressants (n = 226 patients and n = 557 controls) [22] ; to venlafaxine (n = 112 [27] ; and to citalopram (STAR*D study: n = 1953 [24] and n = 139 [20] ). No effects were shown in response to all antidepressants pooled together in a homogenous population of Caucasian patients evaluated by the HDRS: (n = 225 [21] ; and n = 396 patients and n = 295 controls [23] ): to SSRIs in Caucasian patients: paroxetine and fluvoxamine (n = 207 [20] ); paroxetine, fluvoxamine and citalopram (n = 86 [26] ); paroxetine (n = 49 [15] ); and fluoxetine (n = 64 [25] ).
Among the studies mentioned above, only four studied the association between COMT Val(108/158)Met, rs4680 genetic polymorphism and the response to venlafaxine [17, 19, 22, 27] . One study showed that Val/Val genotypes had a better improvement than Met/Met genotypes [17] , and three studies showed no association between COMT Val(108/158)Met, rs4680 genetic polymorphism and the response to venlafaxine [19, 22, 27] .
Therefore, we aimed to investigate whether the COMT Val (108/158)Met, rs4680 genetic polymorphism could be a biomarker for the prediction of venlafaxine efficacy in patients treated in psychiatric settings in a cohort of well-phenotyped and homogenous MDD patients followed after ADD introduction.
Materials and Methods
Study population. The METADAP cohort is a 6-month prospective, multi-centre, real-world setting, treatment study, including 624 in-or outpatients of various ethnicities suffering from a unipolar major depressive episode (MDE) in a context of major depressive disorder (MDD) (DSM-IVTR) and requiring a new antidepressant treatment. The antidepressant treatment had to be a monotherapy. The drug and its dose were left to the treating psychiatrist, using 'real-world' treatment options [28, 29] . Data were collected from November 2009 to March 2013 in six university psychiatry departments in France. Written informed consent was obtained from all patients participating in this study.
Patients were included based on the following criteria: aged 18-65 years, with a current MDE (with a minimum score of 18 at the Hamilton Depression Rating Scale-17 items (HDRS-17) [30] ) in a context of MDD. Patients with psychotic symptoms, bipolar disorders, psychotic disorders, eating disorders, current substance abuse or dependence, pregnancy, organic brain syndromes or severe unstable medical conditions were not included. Patients receiving antipsychotics or mood stabilizers before inclusion and/or for 4 months or more during the last year were not included. They were evaluated for depression symptoms at the start of the treatment (M0) and 1 month (M1), 3 months (M3) and 6 months (M6) later.
Our sample is the subgroup of 206 Caucasian patients treated with venlafaxine. Among them, 180 patients could be genotyped for COMT (Val108/158Met, rs4680) genetic polymorphism, but DNA could not be amplified for the remaining 26 patients. The patients who prematurely dropped out of the study between the baseline and the first month of treatment, between the first and the third and between the third and the sixth month were excluded from the analyses. The dropout reasons were as follows: stop of the antidepressant drug, prescription of unauthorized drugs, change of diagnosis, investigator's decision, patient's decision or other reason.
Genotyping. Genomic DNA was extracted from circulating blood leucocytes using Gentra Puregene Blood Kits according to the manufacturer's protocol (Qiagen, S.A., Courtaboeuf, France) and was stored at À20°C. Genotyping of Val(108/158)Met, rs4680 was performed using the Fluidigm SNP Type Assays â according to the manufacturer's recommendations. The assays are based on allelespecific PCR SNP detection chemistry using the BioMark â HD System (Fluidigm, San Francisco, CA, USA). The call rate for the final set of SNPs was 99%. The COMT genotypes were evaluated as blind samples. Each analysis included positive and negative control for quality assurance. Patients were classified into three genotypes: Val/Val, Val/Met and Met/Met. The METADAP study was approved by the Ethics Committee of Paris-Boulogne, France, and conformed to international ethical standards that cover all genotype procedures.
Venlafaxine efficacy. Clinical response was assessed using the HDRS score. The COMT Val(108/158)Met, rs4680 genotype was the explanatory variable, and the variables to be explained were HDRS score, HDRS score improvement over time, response rate and remission rate. The HDRS score improvement over time was defined by the percentage of the difference between the HDRS score at the follow-up and the HDRS score at baseline divided by the HDRS score at baseline. Response was defined by a decrease in the HDRS score of at least 50% from baseline to follow-up (M1, M3 or M6).
Remission was defined by a HDRS score of 7 or less at follow-up (M1, M3 or M6) [28, 29] . Regarding the responder status, we observed more responders in the Val/Val and Val/Met groups, and this difference was significant only at M3 in bivariate analyses (p = 0.03). In mixed models, the responder status was no more associated with COMT Val(108/158)Met, rs4680. No association between COMT Val(108/158)Met, rs4680 genetic polymorphism and HDRS remission was shown in bivariate analyses and mixed models (table 1) .
Discussion
The main finding of this study is that COMT Val(108/158) Met, rs4680 genetic polymorphism cannot be recommended as a biomarker for the prediction of venlafaxine efficacy in Caucasian patients treated in psychiatric settings. Nevertheless, when the genotypes were analysed independently, Val/Val, Val/Met and Met/Met carriers showed an improvement to venlafaxine over time.
In our study, the frequency of COMT Val(108/158)Met, rs4680 genetic polymorphism was consistent with the most data in the literature for depressed Caucasian patients (52.6% for Val allele carriers), whereas in the healthy Caucasian population, the frequency of the Val allele was 49.6% [20, 31] . However, Hopkins et al. [17] showed in their study that the frequency of the Val allele among all healthy and depressed randomized European individuals was 51.42%. The allele frequency of COMT Val(108/158)Met, rs4680 genetic polymorphism is ethnicity-dependent [31] . Indeed, for the Asian ancestry, the Val allele had a frequency of 60.5% for the depressed population and 65.9% for the healthy population [31, 32] , whereas Hopkins et al. [17] showed in his study that the Val allele of all healthy and depressed randomized African American individuals had a frequency of 68.69%.
In our study, we found that all genotypes improved over time, but no significant difference between the three genotypes was shown. In the double-blind, 8-week, randomized study with patients treated with venlafaxine, Hopkins et al. [17] showed a different result. The clinical improvement of Val/Val genotypes treated with venlafaxine versus placebo was better than that of Met/Met after 8 weeks of treatment. However, the number of patients treated with venlafaxine in the Hopkins study was less important than the number of the patients in our study. Moreover, this study included 25% of African American patients and 75% of Caucasian patients because they decided to increase the power to separate responses between the COMT genotypes by including individuals with higher frequency of Val allele such as African ancestry [17] .
On the other hand, our results are in agreement with the three other studies of patients treated with venlafaxine that showed no association between COMT Val(108/158)Met, rs4680 genetic polymorphism and response to venlafaxine. In the first study of 112 Caucasian patients treated with venlafaxine alone, Narasimah et al. [27] showed no association between COMT Val(108/158)Met, rs4680 and venlafaxine treatment outcome after 6 months of treatment. However, the patients did not have MDD but generalized anxiety disorder evaluated by the HAM-A. In the second study with mixed ADD, a larger naturalistic study of 226 unrelated Caucasian patients with MDD and a control group of 557 healthy individuals after 6 weeks of treatment, Baune et al. [22] showed no association between COMT Val(108/158)Met, rs4680 and venlafaxine response. In this study, only 45 patients were treated with venlafaxine as a monotherapy. In the third study of 184 Korean patients and 200 Korean controls, Chiesa et al. [19] observed no association of the COMT Val(108/158)Met, rs4680 genetic polymorphism with depressive symptom improvement after an average of 7.42 weeks of treatment with venlafaxine in 52 patients. In our study, among the three genotype groups, we observed a very close HDRS score at baseline. Interestingly, in the group of patients who had never received an antidepressant treatment before, the Val/Val genotype group had a more important severity of depression at baseline, and we observed 4 points of difference on the HDRS score compared to Met/ Met patients. Even if this difference is not significant, the meta-analysis of Wang et al. [31] showed the same results: the Val allele carriers of Caucasian ancestry tend to have a greater likelihood of becoming depressed than the Met carriers, while the Met allele is associated with early onset of depression in the Asian population. Moreover, a European multi-centre study found the same outcome that the Val allele was associated with the early onset of depression in the Caucasian population. Furthermore, individuals with the Val/Val genotype seem to have a lower level of transsynaptic catecholamines due to an increased COMT activity which leads to an increased degradation of norepinephrine and dopamine [33] . Massat et al. [33, 34] showed in a large cohort of Caucasian patients that the Val allele, especially the Val/Val genotype, may predispose to early onset in MDD patients.
The outcome of our study showed that there is no significant difference in improvement over time between the Val/ Val, Val/Met and Met/Met carriers after the 6 months of venlafaxine even if the Val/Val genotype was described to have the highest enzyme activity [6] . Venlafaxine and its main active metabolite, the O-desmethylvenlafaxine, are both pharmacologically active and inhibit both serotonin and norepinephrine uptake, with a potency greater for the serotonin at low doses (up to 150 mg) and the norepinephrine reuptake process at higher doses (225 mg or higher) [35] . It also inhibits to a lesser extent the reuptake of dopamine [36] . The clinical response is a complex phenomenon in which the interaction between noradrenergic, dopaminergic and serotoninergic systems makes it impossible for dopamine not to be involved in the response to venlafaxine [4] . COMT inactivates norepinephrine and dopamine, and therefore, it should have an important impact on venlafaxine efficacy only at higher doses [6] . Our results show that the venlafaxine dose is an important confounding factor. Moreover, higher COMT activity for the Val/Val carriers when the norepinephrine transporter (NET) is inhibited by venlafaxine could decrease the bioavailability of norepinephrine and dopamine, compared with Met carriers who show an increased pool of norepinephrine [4, 17] . Nevertheless, the decreased bioavailability of norepinephrine and dopamine in the synaptic cleft could lead to an increase in serotonin concentration that might explain the lack of association between the COMT Val(108/158)Met genotype and the venlafaxine efficacy. Another study evaluating the association between COMT Val(108/158)Met, rs4680 and the milnacipran response, which like venlafaxine blocks the serotonin and norepinephrine transporters, showed a positive association with a greater effect for Val carriers [15] . Bupropion is another antidepressant that inhibits both the norepinephrine and dopamine transporter. Pooled analyses that combined samples from two separate pharmacogenetic trials in more than 700 European patients report evidence of bupropion moderation of a smoking cessation outcome. This study showed that COMT Val(108/158)Met had a moderating effect in altering the efficacy of bupropion on time to first lapse [37] .
Venlafaxine is metabolized by CYP2D6 and CYP2C19 in its main metabolite, O-desmethylvenlafaxine. To the best of our knowledge, until now, only three studies have examined the influence of CYP2D6 and CYP2C19 genetic polymorphisms on venlafaxine treatment response and prediction of venlafaxine efficacy in depressed patients treated in natural psychiatric clinical settings [38] [39] [40] . In all of them, no relationship between genotype and treatment response was shown. We have recently shown in our study on METADAP cohort on the same patients treated with venlafaxine that there was no association between the CYP2D6 and CYP2C19 genotype and venlafaxine efficacy [41] . Therefore, as these studies have not shown a strong correlation of CYP2D6 and CYP2C19 with venlafaxine efficacy, this confounding factor was not included in our mixed models.
Furthermore, gene-gene interaction among a high number of genes belonging to the same pathways should be considered for understanding complex diseases such as MDD [19] . Likewise, two studies showed that COMT Val(108/158)Met, rs4680 interacts with 5-HT gene transporter in anxiety and personal characteristics [42, 43] , while another study showed no association of COMT and dopamine receptor 2 (DRD2) with the clinical outcome of MDD [19] .
Our study has a few important strengths. Firstly, it was a naturalistic study representing 'real-life' patients and shortening the gap between research and practice. Secondly, it had an evaluation until the sixth month of treatment, which is longer than the duration of the other three studies of depressed patients treated with venlafaxine that had only 6-8 weeks of duration evaluated by the HDRS [17, 19, 22] . The one study with the same periods of time is that of Narasimhan et al. [27] on patients with a generalized anxiety disorder treated with venlafaxine evaluated by the HAM-A during 6 months. However, an evaluation of at least 8 weeks is necessary as the team of Tsai et al. [12] showed in a sample of 334 Chinese patients that the influence of COMT Val(108/158)Met, rs4680 can become significant during the second month of treatment. Thirdly, in our study, the patients had homogenous clinical characteristics of MDD at baseline, especially the HDRS score. They were all Caucasian and predominantly female, which represents the reality of MDD, and were all treated with the same drug. Fourthly, the sample size of depressed patients of our study was the highest compared to the three association studies evaluating venlafaxine [17, 22, 27] , and our study had almost the same size as the study of Korean patients by Chiesa et al. (n = 184 [19] ).
There are a few limitations of this study that should be considered. Firstly, our study was a naturalistic study. The lack of randomization may lead to biases related to individual characteristics, environmental influences and their respective treatment response. Secondly, we did not measure compliance, which could have a very important impact in pharmacogenetics studies. Thirdly, the attrition rate of our cohort was 39.04% at the third month of treatment and 29.62% at the sixth month of treatment. Yet, our attrition rate was similar to the attrition rate of the main naturalistic study of ADD with MDD patients, the STAR*D cohort. The attrition rate of the STAR*D cohort was 58.2% of patients who dropped out from the study before the third month of treatment [44] . Moreover, in a longitudinal study of depressive symptoms, Chang et al. [45] showed that 53.10% of the patients dropped out before or at the sixth evaluation. However, attrition is a problem faced by all longitudinal epidemiological studies and the 'real-world' treatment options [46] .
In conclusion, our study shows that COMT Val(108/158) Met, rs4680 genetic polymorphism showed no effect on depressive symptom improvement of venlafaxine in a Caucasian sample treated in a psychiatric setting. Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission such as COMT Val(108/158)Met do not contribute to shape the response to venlafaxine and COMT Val(108/158)Met, rs4680 genetic polymorphism cannot be recommended as a biomarker for the prediction of venlafaxine in patients treated in psychiatric settings. Further clinical studies are needed to confirm our result and explore a biomarker with a panel of all genes comprising the dopaminergic, serotonergic and noradrenergic pathways in clinical settings.
